{"filings":[{"id":96476,"accession_number":"0001104659-26-055264","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q1 2026 net loss $6.1M; cash $25.1M; NXP900 Phase 1b data expected summer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $25.1M as of March 31, 2026, down from $31.6M at Dec 31, 2025.","Net loss $6.1M for Q1 2026 vs $5.3M in Q1 2025, increase driven by R&D and G&A costs.","R&D expenses $4.1M, up $0.4M YoY; G&A $2.2M, up $0.3M YoY.","NXP900 Phase 1b clinical program enrolling patients in US; monotherapy and combination arms ongoing.","Preliminary Phase 1b data readout for NXP900 expected in summer 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110409,"accession_number":"0001104659-26-013049","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma reports FY2025 net loss $26.4M; cash $31.6M; NXP900 program advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.4M for FY2025 vs $19.0M in FY2024; includes $6.0M stock-based comp and $2.4M milestone license fees.","Cash and equivalents $31.6M at Dec 31, 2025, up from $18.5M; funded by public offering and ATM facility.","R&D expenses $18.2M (up from $12.9M), G&A $9.4M (up from $6.9M); finance income $1.1M.","NXP900 Phase 1b monotherapy enrolling; combination with osimertinib (EGFR-mutated NSCLC) enrolling; lorlatinib combo pending.","CEO expects current cash to fund operations through multiple Phase 1b milestones into H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126996,"accession_number":"0001104659-25-105953","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q3 net loss $7.5M; cash $35.4M; NXP900 Phase 1b underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $35.4M at Sep 30, 2025, up from $18.5M at Dec 31, 2024; runway into 3Q2027.","Net loss $7.5M (Q3 2025) vs $4.2M (Q3 2024); increase driven by $2.0M NXP900 milestone expense.","R&D expenses $5.8M (Q3 2025) vs $2.8M (Q3 2024), reflecting clinical progress.","NXP900 Phase 1b single-agent portion initiated; combination arm expected by year-end 2025.","Phase 1a dose escalation and drug-drug interaction study completed with pharmacodynamic responses at clinically relevant doses."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143788,"accession_number":"0001104659-25-093144","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nuvectis Pharma appoints biotech executive Juan Sanchez, MD to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Juan Sanchez, MD appointed to board effective Sept 22, 2025; term expires at 2026 annual meeting.","Sanchez served as VP of Corp Comm & IR at Intra-Cellular Therapies, acquired by J&J for $14.6B in April 2025.","He brings 30+ years experience in biotech, capital markets, and clinical medicine.","Company plans to start Phase 1b program for NXP900, a precision oncology drug candidate.","No arrangements or family relationships; no material transactions per Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143787,"accession_number":"0001104659-25-073967","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis reports Q2 net loss of $6.3M; NXP900 Phase 1a complete; cash ~$39M proforma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.3M for Q2 2025 vs $4.4M for Q2 2024; increase driven by NXP900 DDI study and stock-based compensation.","Cash and equivalents $26.8M at June 30; after July ATM from healthcare investor, proforma ~$39M; expected to fund into 2H 2027.","NXP900 becomes lead candidate; Phase 1a dose escalation and DDI study completed; Phase 1b program initiation imminent.","NXP800 exploring opportunities in endometrial and prostate cancer; updates expected in coming months.","R&D expenses $3.6M (incl. $1.8M stock-based comp); G&A $3.0M (incl. $1.8M stock-based comp) for Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162054,"accession_number":"0001104659-25-059435","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvectis Pharma shareholders elect director, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 14,605,167 shares (61.86%) present out of 23,606,443 outstanding shares.","Class III director James Oliviero elected with 9,882,555 votes for, 240,327 against, 782 abstentions.","Ratification of Kesselman & Kesselman as independent auditor approved with 14,561,983 votes for, 40,324 against.","All proposals passed as detailed in the April 28, 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162053,"accession_number":"0001104659-25-046845","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma establishes $60M ATM with Leerink Partners; terminates prior HC Wainwright program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New ATM agreement with Leerink Partners to sell up to $60M of common stock; 3.0% commission on gross proceeds.","Prior ATM with H.C. Wainwright for up to $40M terminated; ~$18.6M had been sold under that program.","No costs or payments associated with termination of prior ATM.","Sales will be made as at-the-market offerings on Nasdaq subject to customary conditions.","Proceeds from any sales will be used for general corporate purposes as described in the prospectus supplement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162052,"accession_number":"0001104659-25-044838","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q1 2025 net loss $5.3M; cash $29.9M; NXP900 Phase 1b advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $29.9M as of Mar 31, 2025, up from $18.5M at Dec 31, 2024, driven by $14.0M net public offering proceeds.","Net loss $5.3M for Q1 2025 vs $4.2M in Q1 2024; R&D expenses $3.7M, G&A $1.9M.","NXP900 Phase 1a data at AACR showed robust pharmacodynamic response; Phase 1b enrollment in specific genetic alterations pending.","NXP800 Phase 1b study in ARID1a-mutated ovarian cancer enrolling; update expected in two months.","Completed $15.5M financing extending projected cash runway into Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180084,"accession_number":"0001104659-25-016779","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma reports FY2024 net loss of $19.0M; follow-on offering extends cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $18.5M as of Dec 31, 2024, down from $19.1M; net loss $19.0M, vs $22.3M in 2023.","NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; updated data expected Q2 2025.","NXP900 Phase 1a dose escalation continues; Phase 1b program anticipated to begin mid-2025.","Follow-on offering completed Feb 2025 raised $15.5M gross, extending cash runway into 2027.","NXP800 granted Orphan Drug Designation by FDA for ARID1a-deficient ovarian, fallopian tube, and peritoneal cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180083,"accession_number":"0001104659-25-009813","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma prices $13.5M public offering at $5/share; full over-allotment exercised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 2.7M shares at $5.00 for $13.5M gross; underwriter fully exercised over-allotment of 405k shares, total gross $15.5M, net ~$14.4M.","Net proceeds to fund development of NXP800 (Phase 1b ARID1a-mutated ovarian cancer) and NXP900 (Phase 1a SRC kinase inhibitor).","Lucid Capital Markets sole book runner; offering closed February 6, 2025, after option exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196879,"accession_number":"0001104659-24-114097","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma Q3 2024 net loss $4.2M; NXP800 data update expected November","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.2M in Q3 2024 vs $5.9M Q3 2023; R&D expenses $2.8M vs $4.5M.","Cash, cash equivalents and short-term investments $17.2M as of Sep 30, 2024 (vs $19.1M Dec 31, 2023); runway into 2026.","NXP800 Phase 1b clinical data update expected November 2024; received FDA Orphan Drug Designation for ARID1a-deficient ovarian cancers.","NXP900 Phase 1a dose escalation: 4 cohorts completed with no DLTs; dose continuing; combo plans in NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213175,"accession_number":"0001104659-24-094609","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.","CEO Ron Bentsur noted prevalence exceeds 200,000 threshold; designation for a disease subset is uncommon.","Ongoing Phase 1b trial in platinum-resistant ARID1a-mutated ovarian cancer; data update expected fall 2024.","Nuvectis Pharma (NVCT) stock trades on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213174,"accession_number":"0001104659-24-086127","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Q2 2024 net loss narrows to $4.4M; progressing NXP800 and NXP900 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $18.1M at June 30, 2024, down $1.4M from March 31, 2024; net loss $4.4M vs $5.8M YoY.","R&D spend $2.9M (-33% YoY); G&A $1.7M (+13%); interest income $0.2M.","NXP800 Phase 1b ovarian cancer trial enrolling at ~15 US/UK sites; update due fall 2024.","NXP800 investigator-sponsored cholangiocarcinoma trial recruiting; update expected by end of 2024.","NXP900 dose escalation: 3 cohorts complete, no DLTs; planning combo with EGFR/ALK inhibitors in NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232295,"accession_number":"0001104659-24-071261","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvectis Pharma stockholders re-elect directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kenneth Hoberman elected Class II director with 8,026,155 votes for, 809,797 against.","Matthew Kaplan elected Class II director with 8,502,724 votes for, 333,228 against.","Ratification of Kesselman & Kesselman as auditor approved: 12,055,252 for, 31,882 against.","Voting based on 12,227,134 shares present (66.55% of outstanding) on record date April 15, 2024.","All proposals as described in definitive proxy statement filed April 29, 2024 were approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232294,"accession_number":"0001104659-24-057782","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Q1 2024 net loss $4.2M; cash $19.5M; NXP800 Phase 1b data encouraging","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.2M in Q1 2024 vs $4.0M in Q1 2023; cash $19.5M (up from $19.1M in Dec 2023).","NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer shows encouraging preliminary data; FDA Fast Track granted.","NXP900 preclinical data at AACR: robust activity in NSCLC cell lines; synergy with alectinib and osimertinib.","R&D expense $2.7M (+$0.3M YoY); G&A $1.7M flat; interest income $0.2M (vs $0.1M).","Several clinical data updates expected in 2H 2024; cash runway estimated into 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250571,"accession_number":"0001104659-24-030773","cik":1875558,"company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvectis Pharma FY2023 net loss $22.3M; cash $19.1M; NXP800 data update expected March 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $19.1M at Dec 31, 2023, down from $20.0M at Dec 31, 2022.","Net loss for FY2023 was $22.3M vs $19.1M in FY2022; includes $4.7M non-cash stock compensation.","R&D expenses increased to $15.4M from $13.2M; G&A increased to $7.5M from $6.0M.","NXP800 Phase 1b preliminary data update expected in March 2024 for platinum-resistant ARID1a-mutated ovarian cancer.","NXP900 Phase 1a dose escalation initiated; multiple clinical data readouts expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":270560433.6354679,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}